Literature DB >> 14583494

Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells.

Blaine W Robinson1, Michael M Im, Mats Ljungman, Françoise Praz, Donna S Shewach.   

Abstract

Gemcitabine [2',2'-difluoro-2'-deoxycytidine (dFdCyd)] is a potent ionizing radiation sensitizer in solid tumor cells in vitro and in vivo. Previously, we have demonstrated (Shewach et al., Cancer Res., 54: 3218-3223, 1994) a strong correlation between depletion of dATP (caused by dFdCyd diphosphate-mediated inhibition of ribonucleotide reductase) and radiosensitization. In addition, we and others (Latz et al., Int. J. Radiat. Oncol. Biol. Phys., 41: 875-882, 1998; Ostruszka and Shewach, Cancer Res., 60: 6080-6088, 2000) have shown that the accumulation of cells in S phase prior to irradiation is also important for radiosensitization with dFdCyd. This led us to hypothesize that the incorporation of incorrect nucleotides because of the dATP pool imbalance was important for radiosensitization with dFdCyd, and, therefore, cells deficient in mismatch repair (MMR) would exhibit greater radiosensitization. We tested this hypothesis by evaluating the ability of HCT116 colon carcinoma cell lines, which differ in MMR proficiency, to be radiosensitized by dFdCyd. The MMR-proficient cell line (HCT116 + ch3) was more sensitive to dFdCyd alone than were the MMR-deficient cell lines (HCT116, HCT116 + ch2, and HCT116 p53(-/-)). Interestingly, the MMR-proficient cells could not be radiosensitized at concentrations of dFdCyd <or=IC(90), although extremely high concentrations of dFdCyd (>IC(96)) enhanced cell killing with radiation. In contrast, the MMR-deficient cells were radiosensitized at concentrations of dFdCyd <or=IC(50), with radiation enhancement ratios of approximately 1.5. Cell cycle analysis, using dual parameter flow cytometry, demonstrated that all of the cell lines accumulated in S phase after dFdCyd treatment, and, shortly after irradiation, a prominent but transient G(2)-M block was observed. In the MMR-deficient cells, the IC(50) for dFdCyd produced a >or=80% decrease in dATP within 4 h after drug addition, and this low dATP level was maintained for another 12-20 h. Although the IC(50) of dFdCyd was unable to sustain a >80% decrease in the dATP level in the MMR-proficient cells, the IC(90) did achieve this level of dATP depletion; however, it was unable to radiosensitize the MMR-proficient cells. Similar results were obtained with HCT116 cells, in which the MMR deficiency was corrected by transfection with a vector containing the hMLH1 cDNA. In addition, the deletion of p53 did not increase radiation enhancement ratios. These results demonstrate that MMR deficiency promotes radiosensitization with dFdCyd. We suggest that dATP depletion produces errors of replication in MMR-deficient cells, which, if left unrepaired, enhances cell death by ionizing radiation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14583494

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Drug metabolism and homologous recombination repair in radiosensitization with gemcitabine.

Authors:  Michael M Im; Sheryl A Flanagan; Jeffrey J Ackroyd; Donna S Shewach
Journal:  Radiat Res       Date:  2015-01-07       Impact factor: 2.841

2.  Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer.

Authors:  Xiaoqun Dong; Li Jiao; Yanan Li; Douglas B Evans; Huamin Wang; Kenneth R Hess; James L Abbruzzese; Donghui Li
Journal:  J Clin Oncol       Date:  2009-02-23       Impact factor: 44.544

Review 3.  Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review.

Authors:  Meredith A Morgan; Leslie A Parsels; Jonathan Maybaum; Theodore S Lawrence
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

4.  In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells.

Authors:  An Wouters; Bea Pauwels; Filip Lardon; Greet G O Pattyn; Hilde A J Lambrechts; Marc Baay; Paul Meijnders; Jan B Vermorken
Journal:  BMC Cancer       Date:  2010-08-19       Impact factor: 4.430

5.  Single nucleotide polymorphism in RECQL and survival in resectable pancreatic adenocarcinoma.

Authors:  Ronald T Cotton; Donghui Li; Steven E Scherer; Donna M Muzny; Sally E Hodges; Robbi L Catania; Agnieszka K Witkiewicz; Jonathan R Brody; Eugene P Kennedy; Charles J Yeo; F Charles Brunicardi; Richard A Gibbs; Marie-Claude Gingras; William E Fisher
Journal:  HPB (Oxford)       Date:  2009-08       Impact factor: 3.647

6.  Gemcitabine-mediated radiosensitization of human soft tissue sarcoma.

Authors:  James D Murphy; David R Lucas; Yash R Somnay; Daniel A Hamstra; Michael E Ray
Journal:  Transl Oncol       Date:  2008-03       Impact factor: 4.243

7.  Honokiol as a Radiosensitizing Agent for Colorectal cancers.

Authors:  Zhiyun He; Dharmalingam Subramaniam; Zhongtao Zhang; Youcheng Zhang; Shrikant Anant
Journal:  Curr Colorectal Cancer Rep       Date:  2013-12

8.  Digalloylresveratrol, a novel resveratrol analog inhibits the growth of human pancreatic cancer cells.

Authors:  Philipp Saiko; Geraldine Graser; Benedikt Giessrigl; Marie-Thérèse Steinmann; Heike Schuster; Andreas Lackner; Michael Grusch; Georg Krupitza; Walter Jaeger; Venkateswarlu Somepalli; Trimurtulu Golakoti; Monika Fritzer-Szekeres; Thomas Szekeres
Journal:  Invest New Drugs       Date:  2013-08-14       Impact factor: 3.850

9.  MLH1 deficiency enhances tumor cell sensitivity to ganciclovir.

Authors:  J J O'Konek; P D Boucher; A A Iacco; T E Wilson; D S Shewach
Journal:  Cancer Gene Ther       Date:  2009-03-20       Impact factor: 5.987

10.  Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2.

Authors:  Sarah A Martin; Afshan McCarthy; Louise J Barber; Darren J Burgess; Suzanne Parry; Christopher J Lord; Alan Ashworth
Journal:  EMBO Mol Med       Date:  2009-09       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.